First experiences and results of the mometasone-eluting stent in the treatment of patients with chronic rhinosinusitis with polyposis
18 April 2018 (online)
Patients who underwent a funtional endoskopic sinus surgery suffer from early postoperqtive complications such as inflammation, swelling, stenosis. Later on many patients need a revision operqtion because of recurrence polyposis. Mometason-eluting stents prevent a stenosis of the sinus ostia. They provide reductions in postoperative complications such as swelling and wound healing disorder.
The patients with chronic rhinosinusitis who underwent a endonasal sinus surgery were implanted with a mometason-eluting stent. The Propel mometasone eluting stents (Intersect ENT, Palo Alto, CA) were used as a standard Propel stent or as Propel mini. We evaluated the local tolerability of the stents and the postoperative complication rate.
We could not see any dislocation of the stents in the endoskopic controll. The postoperative treatment was optimized by the wide sinus ostia. The stents were well tolerated and their removal was without complications. The postoperative complications such as swelling of the mucosa, inflammation and stenosis were observed less in these patients in comparison to others.
The drug-eluting stents are a novel approach in the reduction of postoperative complications in the sinus surgery. High cost is one of the disadvantages of these stents. More studies which show a benefit of the stents may better their cost effectiveness.
No conflict of interest has been declared by the author(s).